巨星醫療控股(02393.HK)擬6.75億元收購上海安百達集團餘下30%股權
格隆匯 8 月 10日丨巨星醫療控股(02393.HK)發佈公告,有關公司擬收購上海安百達集團公司70%股本權益,收購已於2015年5月完成。根據原股份轉讓協議,當中訂明如上海安百達集團公司截至2017年12月31日止三個年度的合併純利能夠達到原股份轉讓協議所列的年度保證溢利,則買方應收購各上海安百達集團公司餘下30%股本權益,代價參照上海安百達集團公司的公平值計算,相當於上海安百達集團公司截至2017年12月31日止年度合併純利總額(經買方委任的核數師審核)的10倍市盈率的30%,代價最高為人民幣6.75億元。
按照國際財務報告準則計算,上海安百達集團公司截至2017年12月31日止三個年度的合併純利達到原股份轉讓協議所列的年度保證溢利。經長時間商討股份轉讓協議的相互條款後,買方已訂立新的獨立股份轉讓協議,以收購上海安百達集團公司餘下30%股本權益。原股份轉讓協議所列關於收購事項的條款將於股份轉讓協議籤立後依然生效。
2020年8月7日,買方、該等賣方及上海安百達集團公司訂立股份轉讓協議,據此,買方有條件同意於2021年8月31日或之前分三期收購上海安百達集團公司餘下30%股本權益,代價為人民幣6.75億元。
於該公佈日期,上海安百達集團公司為公司間接非全資擁有70%權益的附屬公司。收購事項完成後,上海安百達集團公司將為公司的間接全資附屬公司。上海安百達集團公司為於中國成立的有限責任公司,主要於中國的體外診斷行業從事銷售及經銷業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.